CHL1-AS2: A Promising Drug Target and Biomarker for Cancer (G101927174)

Target Name: CHL1-AS2

NCBI ID: G101927174

CHL1-AS2

Other Name(s): CHL1 antisense RNA 2 | CHL1 antisense RNA 2 (non-protein coding) | CHL1-AS2 variant 1 | Uncharacterized protein LOC101927174

CHL1-AS2: A Promising Drug Target and Biomarker for Cancer

CHL1-AS2 (CHL1 antisense RNA 2) is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. CHL1-AS2 is a negative regulator of the myostatin gene, which encodes a protein that can inhibit muscle growth and is often used in the treatment of cancer. In this article, we will discuss the research on CHL1-AS2 as a drug target and its potential as a biomarker.

CHL1-AS2 as a drug target

CHL1-AS2 has been shown to be a promising drug target for several reasons. Firstly, CHL1-AS2 has been shown to play a role in the regulation of cell growth and differentiation. Studies have shown that CHL1-AS2 can inhibit the growth of cancer cells and induce cell death, suggesting that it may have a potential as a cancer therapeutic. Secondly, CHL1-AS2 has been shown to have a negative impact on the survival of cancer cells. By inhibiting the activity of CHL1-AS2, researchers have found that they can increase the survival of cancer cells, suggesting that it may be a useful target for cancer treatments.

CHL1-AS2 as a biomarker

CHL1-AS2 has also been shown to be a potential biomarker for several diseases, including cancer. By using techniques such as qRT-PCR, researchers have shown that CHL1-AS2 is expressed in various tissues and can be used as a marker for cancer diagnosis and progression. For example, studies have shown that CHL1-AS2 is downregulated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that CHL1-AS2 may be a useful biomarker for these diseases.

CHL1-AS2 as a potential therapeutic

In addition to its potential as a drug target, CHL1-AS2 has also been shown to have a potential as a therapeutic. By using techniques such as RNA interference, researchers have shown that CHL1-AS2 can be used to knockdown the activity of CHL1, which encodes the myostatin gene. This suggests that CHL1-AS2 may be a useful therapeutic for diseases that are caused by the over- activity of the myostatin gene.

Conclusion

In conclusion, CHL1-AS2 is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. CHL1-AS2 has been shown to be a potential drug target and biomarker for several diseases, including cancer. Further research is needed to fully understand the potential of CHL1-AS2 as a therapeutic.

Protein Name: CHL1 Antisense RNA 2

The "CHL1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHL1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets